Use of plasma Renin activity to monitor mineralocorticoid treatment in dogs with primary hypoadrenocorticism: desoxycorticosterone versus fludrocortisone
| Autor: | Felicitas S Boretti, Claudia E Reusch, J Nussberger, Barbara Riond, M E Baumstark, Nadja S Sieber-Ruckstuhl, M W Baumstark |
|---|---|
| Přispěvatelé: | University of Zurich, Sieber-Ruckstuhl, Nadja S |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty 10253 Department of Small Animals medicine.drug_class 3400 General Veterinary Fludrocortisone Standard Article Plasma renin activity Canine Dogs Addison Disease Mineralocorticoids Internal medicine Renin Renin–angiotensin system Adrenal insufficiency medicine Desoxycorticosterone pivalate Animals Dog Diseases Hormone replacement Desoxycorticosterone 630 Agriculture General Veterinary business.industry Therapeutic effect Fludrocortisone Acetate medicine.disease Standard Articles 10187 Department of Farm Animals Endocrinology Mineralocorticoid 570 Life sciences biology Female Therapy business hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Journal of Veterinary Internal Medicine, vol. 28, no. 5, pp. 1471-1478 Journal of Veterinary Internal Medicine |
| Popis: | Background Measurement of plasma renin activity (PRA) is the gold standard for monitoring mineralocorticoid treatment in humans with primary hypoadrenocorticism (PH). Objectives To compare PRA in dogs with newly diagnosed PH, dogs with diseases mimicking PH, and healthy dogs, and evaluate measurement of PRA to monitor therapeutic effects in dogs with PH treated with different mineralocorticoids. Animals Eleven dogs with newly diagnosed PH (group 1), 10 dogs with diseases mimicking PH (group 2), 21 healthy dogs (group 3), 17 dogs with treated PH (group 4). Methods In group 1, PRA was measured before treatment and at different times after initiating treatment. In groups 2 and 3, PRA was measured at initial presentation only. In group 4, no baseline PRA was obtained but PRA was measured once or every 1–6 months during treatment. Mineralocorticoid treatment consisted of fludrocortisone acetate (FC) or desoxycorticosterone pivalate (DOCP). Results Plasma renin activity before treatment was increased in dogs with PH compared to normal dogs and dogs with diseases mimicking PH with median activity of 27, 0.8, and 1.0 ng/mL/h, respectively. In dogs with PH, PRA decreased and normalized with mineralocorticoid treatment using DOCP but not with FC. In dogs treated with DOCP, PRA was lower than in dogs treated with FC. Plasma sodium concentrations were higher and potassium concentrations were lower with DOCP treatment compared to FC treatment. Conclusion and Clinical Importance Plasma renin activity is a reliable tool for monitoring mineralocorticoid treatment. DOCP treatment more effectively suppresses PRA compared to FC in dogs with PH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|